Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Brookline, Massachusetts Clinical Trials

A listing of Brookline, Massachusetts clinical trials actively recruiting patient volunteers.

Found (135) clinical trials

A Phase II Trial of Regadenoson in Sickle Cell Anemia

If you are willing to participate in this research study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and procedures are likely to be part of regular sickle cell anemia care and may be done even if it turns …

Phase

2.29 miles

Learn More »

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.

Phase

2.29 miles

Learn More »

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subjects with information available on tumor HRAS status previously generated …

Phase

2.29 miles

Learn More »

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention, to learn whether the drug works in treating a specific disease, in this case, clofarabine to treat LCH. "Investigational" means that the intervention is still being studied. It also means …

Phase

2.29 miles

Learn More »

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

PRIMARY OBJECTIVES: I. To determine the objective response rate (ORR) of cediranib (cediranib maleate) plus olaparib in combination in patients with advanced or metastatic solid tumors of the following tumor types: non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer …

Phase

2.29 miles

Learn More »

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults. Secondary objectives comprise the efficacy and safety of larotrectinib in different NTRK-tumor types.

Phase

2.29 miles

Learn More »

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase …

Phase

2.29 miles

Learn More »

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

PRIMARY OBJECTIVE: I. To determine the objective response rate to trametinib in children with recurrent or refractory juvenile myelomonocytic leukemia (JMML). SECONDARY OBJECTIVES: I. To further define and describe the toxicities of single agent trametinib in children with recurrent or refractory JMML. II. To further characterize the pharmacokinetics of trametinib …

Phase

2.29 miles

Learn More »

Neratinib HER Mutation Basket Study (SUMMIT)

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification. The trial will consist of a screening period, a treatment period, and an end of treatment …

Phase

2.29 miles

Learn More »

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: Primary - Estimate the response, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma (RCC) treated with bevacizumab and high-dose interleukin-2 (IL-2). Secondary - Compare the response and survival of patients with metastatic RCC treated with bevacizumab and high-dose IL-2 with the historical data of patients …

Phase

2.29 miles

Learn More »